Result of General Meeting and Open Offer

RNS Number : 7855D

SkinBioTherapeutics PLC

30 October 2020

 

30 October 2020

SkinBioTherapeutics plc

Results of General Meeting & Open Offer

Total Voting Rights

Director/PDMR Dealings

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders. 

Furthermore, the Open Offer closed for acceptances at 11.00 a.m. on 28 October 2020 with final valid applications from Qualifying Shareholders in respect of 2,806,428 Open Offer Shares.

Accordingly, the Company will raise a total of approximately £4.45 million (before expenses) through the Placing and Open Offer and has thus issued and allotted 27,806,428 new Ordinary Shares (conditional on Admission). An application has been made for the 27,806,428 new Ordinary Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 2 November 2020.

The Company expects to apply the net proceeds of the Fundraising to fund the expansion of its technology pipeline in areas such as haircare, oral and acne, consider commercial opportunities for own label product lines and support the transition of the Company from a virtual operation to one with an in-house scientific capability and related infrastructure.

Following Admission, the Company's issued share capital will comprise 155,889,922 Ordinary Shares, of which none are held in treasury. The above figure of 155,889,922 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 14 October 2020.

Details of the proxy votes received on each resolution by SkinBioTherapeutics' Registrar are set out below:

Resolution		For & Discretionary		Against		Withheld		Total votes cast
		Number of votes	%	Number of votes	%	Number of votes	%
1	Ordinary resolution to authorise the directors to allot shares	49,705,965	100.0%	10,000	0.0%	4,065	0.0%	49,720,030
2	Ordinary resolution to authorise the directors to allot shares	49,700,965	100.0%	15,000	0.0%	4,065	0.0%	49,720,030
3	Special resolution to authorise the directors to disapply pre-emption rights	49,688,465	99.9%	10,000	0.0%	21,565	0.0%	49,720,030
4	Special resolution to authorise the directors to disapply pre-emption rights	49,688,465	99.9%	15,000	0.0%	16,565	0.0%	49,720,030

Directors and other persons discharging managerial responsibility ("PDMRs") have subscribed for shares through the Placing and Open Offer as detailed below.

Director/PDMR	Shares Acquired	Total Holding*	Percentage of Enlarged Share Capital*
Stuart Ashman	125,000	125,000	0.1%
Catherine Prescott	62,500	118,612	0.1%
Stephen France	4,607	193,495	0.1%

* following Admission of the shares on AIM.

For administrative purposes unconnected with the Placing and Open Offer, certain Directors and other PDMRs have transferred the title of their shares in the Company from their existing nominee into certificated form or a different nominee arrangement as detailed below. The transfers have not resulted in a change in their beneficial interest or in the price of the shares.

Director/PDMR	Shares Transferred
Martin Hunt	466,667
Douglas Quinn	444,444
Stephen France	188,888

-Ends-

For more information please contact:

SkinBioTherapeutics plc	Tel: [phone]
Stuart Ashman, CEO Doug Quinn, CFO
Cenkos Securities plc (Nominated Adviser & Broker)	Tel: [phone]
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)
Instinctif Partners	Tel: [phone]
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	[e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotherapeutics.com .

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Stuart John Ashman
2	Reason for notification	Acquisition of shares
a.	Position/Status	CEO
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics Plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Share purchase
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16p	125,000
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	2nd November 2020
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Cathy Prescott
2	Reason for notification	Acquisition of shares
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics Plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Share purchase
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16p	62,500
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	2nd November 2020
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Stephen France
2	Reason for notification	Acquisition of shares
a.	Position/Status	PDMR
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Share purchase
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16p	4,607
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	2nd November 2020
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Martin Hunt
2	Reason for notification	Change in title of ownership of holding
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Transfer of holding
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			nil	466,667
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	22/10/2020
f.	Place of the transaction

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Stephen France
2	Reason for notification	Change in title of ownership of holding
a.	Position/Status	PDMR
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Transfer of holding
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			nil	188,888
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	22/10/2020
f.	Place of the transaction

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Doug Quinn
2	Reason for notification	Change in title of ownership of holding
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Transfer of holding
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			nil	444,444
d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	TBC
f.	Place of the transaction

 

END

 

 

MSCEAFEEDDLEFFA